Ascentage Pharma Group International announced that results from multiple clinical studies of olverembatinib and APG-2575 (lisaftoclax) have been selected for presentations, including two oral reports, at the 65th American Society of Hematology (ASH) Annual Meeting. Olverembatinib was selected for oral reports at the ASH Annual Meeting for the sixth consecutive year, underscoring the significant interest in the drug's efficacy and safety by the global hematology community. Olverembatinib has broad therapeutic potential for the treatment of multiple solid tumors and hematologic malignancies.

Through an oral report, Ascentage Pharma will present the latest results from a randomized, controlled registrational Phase II study in patients with first- and second-generation tyrosine kinase inhibitor (TKI)-resistant chronic myeloid leukemia in the chronic-phase (CML-CP). The data show that, in patients with CML-CP who were resistant/intolerant to TKIs, olverembatinib demonstrated statistically significant and clinically meaningful improvement in event-free survival (EFS), compared with the best available therapy (BAT), meeting the primary endpoint of the study. The other Oral Report featuring early results from a Phase II study of olverembatinib combined with venetoclax and reduced-intensity chemotherapy in treatment-naïve patients with Ph+ ALL, led by Prof. Xiaoyuan Gong of the Institute of Hematology and Blood Diseases Hospital, the Chinese Academy of Medical Sciences Also at this year's ASH Annual Meeting, Ascentage Pharma will release updated results from a US study of olverembatinib in a Poster Presentation.

These data demonstrate the favorable potential clinical benefit of olverembatinib monotherapy and combination regimens in patients with heavily pretreated CML or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) and show the drug's therapeutic effect in patients who had failed prior treatment with ponatinib or asciminib, further demonstrating the drug's potential as a new treatment option to patients with CML or Ph+ ALL worldwide. In addition, multiple other studies of olverembatinib were also selected for Poster Presentations, including one featuring a case series study of liposome mitoxantrone combined with venetoclax, homoharringtonine, and olverembatinib (the MVHO regimen) in pediatric patients with refractory or recurrent acute myeloid leukemia (AML), carried out by a team of investigators including Wenting Hu and Prof. Shuhong Shen of the Department of Hematology & Oncology, Shanghai Children's Medical Center of Shanghai Jiao Tong University School of Medicine. Developed by Ascentage Pharma, APG-2575 (lisaftoclax) is an orally available Bcl-2 inhibitor promising a wide therapeutic window in multiple hematologic malignancies and solid tumors.

The investigational clinical data of lisaftoclax in patients with chronic lymphocytic leukemia (CLL), to be presented at the ASH Annual Meeting this year, once again demonstrate the drug's promising efficacy and favorable tolerability in patients with CLL who were heavily-pretreated and had prior exposure to BTK inhibitors. In two other abstracts on lisaftoclax, results were disclosed from clinical studies of the drug as a single agent and in combination regimens in multiple hematologic malignancies including relapsed/refractory (R/R) multiple myeloma (MM) and AML. The ASH Annual Meeting is one of the largest gatherings of the international hematology community, bringing together the latest and most cutting-edge scientific research in the pathogenesis and clinical treatment of hematologic diseases.

The 65th ASH Annual Meeting will take place on December 9, 2023 to December 12, 2023, both online and in-person in San Diego, the United States.